Nature Made

Tripleflex Glucosamine objected — as amicus curiae — to a class-action settlement that sought to resolve claims that TripleFlex glucosamine supplements were deceptively marketed as being able to improve joint mobility, increase joint flexibility, and reduce joint pain and discomfort, when competent scientific evidence did not support, and even contradicted, these marketing claims.


March 30

The class member’s appeal was voluntarily dismissed.

December 28

A class member who had objected to the fairness of the settlement agreement files a Notice of Appeal indicating he is appealing the Court’s final approval to the Ninth Circuit Court of Appeals.

December 4

After the Final Fairness Hearing, the Court grants final approval of the settlement agreement.

November 29 files reply to Pharmavite’s opposition.

November 27

Pharmavite files an opposition to’s Motion for Leave to file an amicus curiae brief in the case.

November 13 files a brief as amicus curiae opposing the proposed settlement reached by the parties, as well as a Motion for Leave to file the brief.

June 1

The parties file an amended settlement agreement.

April 28

Plaintiffs move for preliminary approval of a settlement agreement.

May 13

Plaintiffs file their complaint (and later amend it in October) against Pharmavite alleging it deceptively markets TripleFlex joint health dietary supplements as helping to improve joint mobility and flexibility and reduce joint pain when the company does not have adequate scientific evidence to support such claims.

* The above events do not represent the entire procedural history of the case, but rather only highlights some key events pertaining to’s involvement in the case.


The Latest


Class-Action Tracker

TripleFlex Supplements

Class Action

TripleFlex Supplements

March 2018: The appeal was voluntarily dismissed, the reasons for which have not been disclosed. December 2017: A federal judge granted final approval of the settlement agreement. Later in December,…